IDSA GUIDELINES Bundle (free trial)

Chronic Kidney Disease in HIV-Infected Patients

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/418521

Contents of this Issue

Navigation

Page 11 of 15

Table 4. Dosing of Antiretroviral Drugs for HIV-Infected Adults With CKD or ESRD (continued) Antiretroviral Drug and Dosing Category Dosage Comments Nucleoside reverse transcriptase inhibitors (NRTIs) (continued) Emtricitabine CrCl ≥50 mL/min 200 mg PO daily CrCl 30-49 mL/min 200 mg PO q48h CrCl 15-29 mL/min 200 mg PO q72h CrCl <15 mL/min 200 mg PO q96h Receiving HD 200 mg PO q96h a Receiving PD Unknown, use with caution (dose reduction needed) Tenofovir disoproxil fumarate CrCl ≥50 mL/min 300 mg PO daily CrCl 30-49 mL/min 300 mg PO q48h is guideline recommends avoiding tenofovir in patients with CrCl <50 mL/ min who are not on HD CrCl 10-29 mL/min 300 mg PO q72-96h Receiving HD 300 mg PO every 7 d a (an additional dose may be needed if >12 h HD per week) Receiving PD Unknown, use with caution (dose reduction needed) Emtricitabine/tenofovir disoproxil fumarate CrCl ≥50 mL/min 200 mg/300 mg PO daily CrCl 30-49 mL/min One tablet PO q48h CrCl <30 mL/min Should not use combination tablet Treatment 10

Articles in this issue

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Chronic Kidney Disease in HIV-Infected Patients